Allena Pharmaceuticals, Inc. P/E ratio

P/E ratio of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/E ratio growth rates and interactive chart. A valuation metric that measures the share price of a stock compared to its earnings per share. A low P/E ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. P/E ratio can be compared to different companies in the same industry or to a company’s own historical valuation.


Highlights and Quick Summary

Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/E ratio of Allena Pharmaceuticals, Inc.

Most recent P/E ratioof ALNA including historical data for past 10 years.

Interactive Chart of P/E ratio of Allena Pharmaceuticals, Inc.


Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.